AMELTOLIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H16N2O
Molecular Weight	240.3003
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=CC(C)=C1NC(=O)C2=CC=C(N)C=C2

InChI

InChIKey=HZIWGOAXOBPQGY-UHFFFAOYSA-N

InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H16N2O
Molecular Weight	240.3003
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800008003 | https://www.ncbi.nlm.nih.gov/pubmed/2016702

Ameltolide (ADD 75073, LY 201116) is a 4-aminobenzamide anticonvulsant patented by Research Corporation Technologies in the USA. Ameltolide is a sodium channel antagonist, it represents a potential therapy for the treatment of epilepsy. Ameltolide had been in phase I clinical trials by Research Corporation Technologies for the treatment of epilepsy. However, this research has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
sodium ion transport 14 Target ID: GO:0006814 Sources: http://adisinsight.springer.com/drugs/800008003 \| https://www.ncbi.nlm.nih.gov/pubmed/9719582	Inhibitor 8297		0.97 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Epilepsy 121 Sources: http://adisinsight.springer.com/drugs/800008003 https://www.ncbi.nlm.nih.gov/pubmed/19000280	Primary		Phase I 428	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1819	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170466362	no
CYP2D6 1891	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170466362	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=170466362	yes [IC50 27.5404 uM]

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P005DYC	https://www.1pchem.com/search?query=1P005DYC
A2B Chem	AC50564	http://a2bchem.com/prod/AC50564
AA Blocks	AA005DEW	http://aablocks.com/goods/Goods/detail?id=AA005DEW
AK Scientific	9769AE	https://aksci.com/item_detail.php?cat=9769AE
Alfa Chemistry	234810	http://www.alfa-chemistry.com/search.aspx?q=234810
Alfa Chemistry	ACM787939	http://www.alfa-chemistry.com/search.aspx?q=ACM787939
Angene	AGN-PC-0JKAZ7	http://www.angenechemical.com/productshow/AGN-PC-0JKAZ7.html
Aronis	BLOCK07235	http://www.aronis.ru/store/index.php?main_page=advanced_search_result&search_in_description=1&keyword=BLOCK07235
AsisChem	C15660	https://asischem.com/catalogsearch/result/?q=C15660
BLD Pharm	BD188701	http://www.bldpharm.com/search/Search.html?keyword=BD188701
ChemBridge	9035824	http://www.hit2lead.com/screening-compounds/9035824
Chemspace	CSC000500771	https://chem-space.com/CSC000500771
Enamine	BBV-019637	http://www.enaminestore.com/catalog/BBV-019637
Enamine	Z111686304	https://www.enaminestore.com/blog/real/Z111686304/
Fluorochem	315771	http://www.fluorochem.co.uk/Products/Product?code=315771
Lab Network	LN00132766	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00132766
Matrix Scientific	25843	http://www.matrixscientific.com/025843.html
MolPort	MolPort-004-300-649	https://www.molport.com/shop/molecule-link/MolPort-004-300-649
Princeton BioMolecular Research	OSSL_116997	http://www.princetonbio.com/order_online?common_id=OSSL_116997
Vitas-M Laboratory	STK360030	http://www.vitasmlab.biz/search/STK360030
Wonderchem	WD07HEO	http://www.wonder-chem.com/search.html?text=WD07HEO
eMolecules	5758305	https://orderbb.emolecules.com/search/#?query=5758305
mcule	MCULE-9326873792	https://mcule.com/MCULE-9326873792/

PubMed

Title	Date	PubMed
Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity--preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties.	1998	9806229

Patents

Sample Use Guides

In Vivo Use Guide

Canine seizure model: from 2 to 15 h following a single 3 mg/kg oral ameltolide dose the mean probability of obtaining a 1 unit reduction in the seizure clinical score severity was greater than 0.80.

Route of Administration: Oral

In Vitro Use Guide

As a function of increasing concentration, ameltolide produced a selective decrease in the afterpotentials of the spontaneous bursts before decreasing the frequency of bursts. The concentration estimated to inhibit the number of afterpotentials per burst by 50% (IC50 value) was 2.7 uM, whereas the ICs0 value estimated to reduce the frequency of bursts was 15 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:46:03 GMT 2023` Edited by `admin` on `Fri Dec 15 17:46:03 GMT 2023`
Record UNII	F83240ZOVE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMELTOLIDE

Official Name

English

LY-201116

Code

English

LY 201116

Code

English

ameltolide [INN]

Common Name

English

AMELTOLIDE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264